BIOMAT Database Logo BIOMAT Database Logo

FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. 1997

T Valerius, and B Stockmeyer, and A B van Spriel, and R F Graziano, and I E van den Herik-Oudijk, and R Repp, and Y M Deo, and J Lund, and J R Kalden, and M Gramatzki, and J G van de Winkel
Department of Medicine III, University of Erlangen, Nürnberg, Germany.

Promising results from clinical trials with unconjugated antibodies stimulated renewed interest in immune effector mechanisms of monoclonal antibodies (MoAbs). We investigated the potential of IgA as antibody isotype for cell- or complement-mediated tumor cell lysis and assessed the potential of its myeloid Fc receptor, FcalphaRI (CD89), as trigger molecule for bispecific antibody (BsAb)-mediated immunotherapy. Comparing hapten-directed antibodies of human IgA2 with IgG1 or IgG3 isotypes, we found all three to mediate effective killing of sensitized tumor target cells in whole blood assays. Analysis of effector mechanisms showed IgG-mediated lysis to be predominantly complement-dependent, whereas IgA-dependent killing was primarily effector cell-mediated. A comparison of effector cell populations in antibody-dependent cell-mediated cytotoxicity (ADCC) showed neutrophils to be most important for IgA-dependent tumor cell killing, involving FcalphaRI as shown with Fc receptor blocking antibodies. Reverse ADCC experiments against target cells sensitized with Fc receptor antibodies, or assays with FcalphaRI-directed bispecific antibodies confirmed FcalphaRI as effective trigger molecule in polymorphonuclear neutrophil (PMN)-mediated lysis. During granulocyte colony-stimulating factor (G-CSF ) therapy, (FcalphaRI x HER-2/neu) bispecific antibodies induced enhanced killing of HER-2/neu positive SK-BR-3 breast cancer cells in whole blood assays. This enhanced cytotoxicity was paralleled by increased PMN counts, which lead to higher effector to target cell ratios in G-CSF-primed blood. Furthermore, bispecific antibodies, directed to FcalphaRI and Candida albicans, enhanced neutrophils' phagocytosis of fungi. In summary, these results identify IgA as an effective antibody isotype for immunotherapy, working primarily via FcalphaRI on neutrophils. They suggest FcalphaRI-directed bispecific antibodies and G-CSF to be an attractive combination for malignant or infectious diseases.

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D011961 Receptors, Fc Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognize and combine with the Fc (crystallizable) portion of immunoglobulin molecules. Fc Receptors,Fc Receptor,Receptor, Fc
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell

Related Publications

T Valerius, and B Stockmeyer, and A B van Spriel, and R F Graziano, and I E van den Herik-Oudijk, and R Repp, and Y M Deo, and J Lund, and J R Kalden, and M Gramatzki, and J G van de Winkel
A novel polymorphism of FcalphaRI (CD89) associated with aggressive periodontitis.
June 2004, Tissue antigens,
T Valerius, and B Stockmeyer, and A B van Spriel, and R F Graziano, and I E van den Herik-Oudijk, and R Repp, and Y M Deo, and J Lund, and J R Kalden, and M Gramatzki, and J G van de Winkel
The Fc receptor for IgA (FcalphaRI, CD89).
March 2004, Immunology letters,
T Valerius, and B Stockmeyer, and A B van Spriel, and R F Graziano, and I E van den Herik-Oudijk, and R Repp, and Y M Deo, and J Lund, and J R Kalden, and M Gramatzki, and J G van de Winkel
Targeting of Porphyromonas gingivalis with a bispecific antibody directed to FcalphaRI (CD89) improves in vitro clearance by gingival crevicular neutrophils.
December 2004, Vaccine,
T Valerius, and B Stockmeyer, and A B van Spriel, and R F Graziano, and I E van den Herik-Oudijk, and R Repp, and Y M Deo, and J Lund, and J R Kalden, and M Gramatzki, and J G van de Winkel
Di-diabody: a novel tetravalent bispecific antibody molecule by design.
August 2003, Journal of immunological methods,
T Valerius, and B Stockmeyer, and A B van Spriel, and R F Graziano, and I E van den Herik-Oudijk, and R Repp, and Y M Deo, and J Lund, and J R Kalden, and M Gramatzki, and J G van de Winkel
FcalphaRI (CD89) alleles determine the proinflammatory potential of serum IgA.
March 2007, Journal of immunology (Baltimore, Md. : 1950),
T Valerius, and B Stockmeyer, and A B van Spriel, and R F Graziano, and I E van den Herik-Oudijk, and R Repp, and Y M Deo, and J Lund, and J R Kalden, and M Gramatzki, and J G van de Winkel
CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.
January 2017, Oncoimmunology,
T Valerius, and B Stockmeyer, and A B van Spriel, and R F Graziano, and I E van den Herik-Oudijk, and R Repp, and Y M Deo, and J Lund, and J R Kalden, and M Gramatzki, and J G van de Winkel
[Development of novel bispecific antibody therapy for multiple myeloma].
January 2024, [Rinsho ketsueki] The Japanese journal of clinical hematology,
T Valerius, and B Stockmeyer, and A B van Spriel, and R F Graziano, and I E van den Herik-Oudijk, and R Repp, and Y M Deo, and J Lund, and J R Kalden, and M Gramatzki, and J G van de Winkel
Crosslinking of the human Fc receptor for IgA (FcalphaRI/CD89) triggers FcR gamma-chain-dependent shedding of soluble CD89.
December 1999, Journal of immunology (Baltimore, Md. : 1950),
T Valerius, and B Stockmeyer, and A B van Spriel, and R F Graziano, and I E van den Herik-Oudijk, and R Repp, and Y M Deo, and J Lund, and J R Kalden, and M Gramatzki, and J G van de Winkel
Complexes of IgA with FcalphaRI/CD89 are not specific for primary IgA nephropathy.
February 2003, Kidney international,
T Valerius, and B Stockmeyer, and A B van Spriel, and R F Graziano, and I E van den Herik-Oudijk, and R Repp, and Y M Deo, and J Lund, and J R Kalden, and M Gramatzki, and J G van de Winkel
A novel brick for bispecific antibody construction.
August 2023, Proteins,
Copied contents to your clipboard!